Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy

Concetta Elisa Onesti1,2, François Boemer3, Claire Josse1,2*, Stephane Leduc3, Vincent Bours2,3 and Guy Jerusalem1,4

Abstract

Background: Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine, an immunosuppressive metabolite involved in T regulatory cell differentiation. Indoleamine 2,3-dioxygenase is expressed in many cancer types, including breast cancer. Here, we analyze kynurenine and tryptophan and their ratio in breast cancer patients and healthy controls.

Methods: Breast cancer patients and healthy controls were prospectively enrolled in our study. All subjects underwent blood sample withdrawal at diagnosis or on the day of screening mammography for the healthy controls. Plasmatic kynurenine and tryptophan were determined on a TQ5500 tandem mass spectrometer after chromatographic separation.

Results: We enrolled 146 healthy controls and 202 women with stages I–III breast cancer of all subtypes. All patients underwent surgery, 126 underwent neoadjuvant chemotherapy with 43 showing a pathological complete response, and 43 underwent adjuvant chemotherapy. We observed significantly higher plasmatic kynurenine, tryptophan and their ratio for the healthy controls compared to patients with breast cancer. We observed a lower plasmatic tryptophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone receptor-positive cancers. Lobular cancers showed a lower ratio than any other histologies. Advanced cancers were associated with a lower tryptophan level and higher grades with an increased kynurenine/tryptophan ratio. Pathological complete response was associated with higher kynurenine values. The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratios were not predictive of survival.

Conclusions: The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratio could differentiate breast cancer patients from healthy controls. The Kyn/Trp ratio and Trp also showed different values according to hormone receptor status, TNM stage, T grade and histology. These results suggest a rapid metabolism in breast cancer, but no associations with outcome or sensitivity to chemotherapy were observed.

Keywords: Indoleamine 2,3-dioxygenase, Kynurenine, Tryptophan, Kynurenine/tryptophan ratio, Immune system, Breast cancer, Circulating biomarkers
Background

Tryptophan (Trp) catabolism is a known mechanism involved in immune system modulation and is widely studied in cancer. Trp is metabolized by indoleamine 2,3-dioxygenase (IDO), by its splice variant IDO2 and by tryptophan 2,3-dioxygenase (TDO) [1]. IDO2 expression is narrower than IDO, and it is inactivated in a large percentage of the population due to some common polymorphisms, namely, R248W, that reduces IDO activity in approximately 90% of individuals, and Y359, which completely abolishes its catalytic function [2]. TDO is expressed at high levels in the liver, where it regulates systemic Trp levels, and in the brain, where it is responsible for the production of neuroactive metabolites, such as kynurenic and quinolinic acid [3]. IDO seems to play a central role in maintaining immune tolerance. Previous studies showed that IDO-deficient mouse models are more susceptible to autoimmune disease, while TDO-deficient mice showed only behavioral alterations [3, 4]. IDO expression is induced in response to some inflammatory cytokines, such as interferon-γ (IFN-γ), acting as an endogenous mechanism able to control an excessive immune response [5]. IDO is expressed by several tumor types and is correlated with lower cytotoxic cells and higher T regulatory (Treg) cell infiltration at the tumor site, poorer outcome and resistance to treatment [6–16].

Trp depletion induces an arrest at the G1 phase of the cell cycle, blocking T-lymphocyte proliferation, and triggers a stress response mediated by the activation of the nonderepressible kinase GCN2 pathway, which is responsible for T-cell anergy and apoptosis [17]. When exposed to low Trp levels, dendritic cells (DC) acquire tolerogenic capacity. DC showed an upregulation of the immunoglobulin-like transcript 3 and 4 inhibitory receptors (ILT3 and ILT4) and a lower expression of costimulatory molecules, such as CD40 and CD80 [18]. The high expression of ILT3 and ILT4 leads to the differentiation of CD4+CD25+Foxp3+ Treg cells [18]. Moreover, Trp catabolites, i.e., kynurenine (Kyn) and its downstream metabolites, acting through the activation of the aryl hydrocarbon receptor (AHR), are also responsible for Treg differentiation and in inhibition of T lymphocytes and natural killer (NK) cells [19, 20].

IDO is expressed in several tumor types, including breast cancer. A retrospective analysis conducted on 203 breast cancer patients showed that none of the tumor samples were negative for IDO staining in immunohistochemistry [21]. Larger, node-positive and estrogen receptor-positive (ER+) tumors were associated with higher IDO expression, while greater vascularized tumors showed lower IDO staining [21]. A greater CD8+ and CD11b+ cell infiltration was observed in low-IDO tumors, while Treg infiltration was not associated with IDO expression in this report [21]. Another study reported a negative association between high stromal IDO and worse disease-free and metastasis-free survival in breast cancer [22].

The plasmatic Kyn/Trp ratio is commonly used as a surrogate indicator of IDO activity, even though it might be an imperfect reflection of the tumor Trp catabolism. Lyon and colleagues observed a higher plasmatic Kyn/Trp ratio in patients affected by breast cancer compared to healthy controls, but not a statistically significant difference in the plasmatic level of the two molecules [23]. Another more recent study showed significantly lower plasmatic Trp and Kyn levels in breast cancer patients than in healthy controls, mainly in estrogen receptor-negative (ER−) tumors and at an advanced tumor stage [24]. Tang and colleagues observed higher Kyn plasmatic levels in ER− compared to ER+ cancers [25]. Overall, the previously mentioned studies did not unequivocally identify an association between tumor characteristics and the plasmatic Kyn, Trp and Kyn/Trp ratio, in addition to not showing an association with outcome, despite what was observed in other diseases [14–16].

In the present study, we analyzed the plasmatic levels of Trp, Kyn and their ratio in a large cohort of stage I–III breast cancer patients undergoing surgery ± neoadjuvant/adjuvant treatment and in healthy controls. The aim of our study was to identify differences in Kyn, Trp and the Kyn/Trp ratios in plasma between healthy and cancerous women to analyze the association of these parameters with outcome, their distribution according to tumor characteristics and their correlation with some tumor and patient characteristics.

Materials and methods

Patients selection

This was an observational prospective study in which stage I–III breast cancer patients treated with surgery with or without adjuvant/neoadjuvant treatment, radiotherapy and hormonal therapy according to clinical practice at the University Hospital of Liège in Belgium between May 2011 and August 2017 were enrolled.

Healthy controls were enrolled between January and November 2014 at the University Hospital of Liège in Belgium before performing a screening mammography and were allocated to the control group after confirmation of the absence of breast disease.

For all breast cancer patients, the following data were collected: ER status, progesterone receptor (PGR) status, HER2 status, Ki67, TNM stage, tumor size, tumor grade, type of treatment, response to chemotherapy for patients who received neoadjuvant chemotherapy (NAC), disease-free survival (DFS) and breast cancer-specific survival (BCSS).
This study was conducted in accordance with the Declaration of Helsinki. The institutional ethics committee approved the protocols, and each patient or healthy control signed informed consent before inclusion in the trial.

**Sample collection and storage**

Blood sample withdrawal into an EDTA tube was performed before receiving any treatment for breast cancer patients or before the day of the screening mammography for healthy controls. After two centrifugation steps for 10 min at 815g and for 10 min at 2500g at 4 °C, plasma was collected in aliquots and stored at −80 °C without thawing cycles until the sample analysis.

**Tryptophan and kynurenine determination**

The plasmatic samples were used to determine the Kyn and Trp concentrations. After the step of protein precipitation with salicylic acid, the Kyn and Trp concentrations were determined on a TQ5500 tandem mass spectrometer after chromatographic separation. The values were calculated by the software Analyst, comparing the spectrometer intensity with known concentrations of internal standards for Trp and Kyn. The final concentrations were expressed in μM/L. Each sample was tested in triplicate, and the mean value was used for the statistical analysis.

**Statistical analysis**

Statistical analyses and graphs were performed using IBM SPSS Statistic v24, MedCalc v19 and Prism v5 GraphPad software.

The co-primary end-points of our study were to assess the different distributions of plasmatic Kyn, Trp and the Kyn/Trp ratio in breast cancer (BC) patients compared to healthy controls (CTRL).

The secondary end-points were to identify the different distribution of plasmatic Kyn, Trp and the Kyn/Trp ratio according to patient and tumor characteristics (age, ER status, PgR status, HER2 status, Ki67%, TNM stage, T stage, N stage, tumor grade, histology, subtype, lymphovascular invasion, response to NAC and relapse in the whole cohort and according to the different BC subtypes), to test the correlation between plasmatic Kyn, Trp and the Kyn/Trp ratio with the continuous variables age, ER%, PgR%, Ki67% and tumor size in mm. An alpha level of 0.05 was accepted for significant results.

Spearman test was performed to analyze the correlation between plasma Kyn and Trp and their ratio with the following continuous variables: age, ER%, PgR%, Ki67% and tumor size in mm. An alpha level of 0.05 was accepted for significant results.

The median values of circulating Kyn, Trp and the Kyn/Trp ratio for cancer patients were calculated and used as cut-offs to classify patients into two groups for each variable. Kaplan–Meier curves for DFS and BCSS were drafted, and the statistical significance was tested by means of a log-rank test, with an accepted alpha level of 0.05. The 5-year DFS and the 5-year BCSS were calculated from the survival tables. The Cox Regression Hazard model was used to calculate the HR for both DFS and BCSS.

**Results**

In total, 348 subjects, 146 of whom were healthy controls (CTRL) and 202 of whom were stage I–III breast cancer (BC) patients, were enrolled in this study between May 2011 and August 2017 at the University Hospital of Liège in Belgium.

The median age for the whole cohort was 54.5 years (range 26–86). In particular, the median age in the group of 202 breast cancer patients was 56 years old (range 26–86), while the median age in the healthy controls group was 53 years old (range 40–74). The median follow-up was 60 months (range 14–96). The patients were classified as stage I in 20.8%, stage II in 55% and stage III in 24.3% of the cases. All the breast cancer subtypes were included in the study: Luminal A in 29.7%; Luminal B in 44.1%; HER2-enriched in 6.9% and triple-negative breast cancer (TNBC) in 19.3% of the cases. All patients underwent surgery and received neoadjuvant/adjuvant chemotherapy, trastuzumab, radiotherapy and hormonotherapy according to cancer characteristics and physician choice. All patient characteristics and treatment details are summarized in Table 1.

Circulating Kyn was significantly lower in the BC patients than in the healthy CTRLs, with a median value of 1.770 ± 0.537 μM/L vs. 1.951 ± 0.708 μM/L (p < 0.0001), respectively. The same observation was found for the Trp value in plasma, which was 44.56 ± 10.83 μM/L and 48.80 ± 14.16 μM/L in the BCs and CTRLs respectively (p < 0.001), and for the plasmatic Kyn/Trp ratio, which was 0.038 ± 0.013 for the BC patients and 0.042 ± 0.019 for the healthy CTRLs (p 0.026) (Table 2 and Fig. 1).

The Kyn and Kyn/Trp ratio in plasma showed a different distribution according to age in the entire
cohort, with a lower plasmatic concentration of Kyn (1.738 ± 0.609 μM/L vs. 1.980 ± 0.643 μM/L, p < 0.0001) and Kyn/Trp ratio (0.036 ± 0.015 vs. 0.043 ± 0.016, p < 0.0001) for patients younger than 54.5 years (Table 2). Consistently, we observed a significant positive correlation between the age and circulating Kyn or Kyn/Trp ratio, with correlation coefficients of 0.295 (p < 0.0001) and 0.300 (p < 0.0001), respectively (Table 3 and Additional file 1: Figure S3).

### Table 1 Patient baseline characteristics

| Characteristic            | Number of patients | % of patients |
|---------------------------|--------------------|---------------|
| Median age: 56 years      |                    |               |
| Range: 26–86 years        |                    |               |
| Histology                 |                    |               |
| Ductal carcinoma          | 172                | 85.1          |
| Lobular carcinoma         | 23                 | 35.4          |
| Other                     | 7                  | 3.5           |
| Subtype                   |                    |               |
| Luminal A                 | 60                 | 29.7          |
| Luminal B                 | 89                 | 44.1          |
| HER2-enriched             | 14                 | 6.9           |
| TNBC                      | 39                 | 19.3          |
| ER status                 |                    |               |
| Positive                  | 145                | 71.8          |
| Negative                  | 57                 | 28.2          |
| PgR status                |                    |               |
| Positive                  | 131                | 64.9          |
| Negative                  | 71                 | 35.1          |
| HER2 status               |                    |               |
| Positive                  | 55                 | 27.2          |
| Negative                  | 147                | 72.8          |
| Ki67                      |                    |               |
| < 20%                     | 74                 | 36.6          |
| ≥ 20%                     | 127                | 62.9          |
| Unk                       | 1                  | 0.5           |
| Stage                     |                    |               |
| I                         | 42                 | 20.8          |
| II                        | 111                | 55            |
| III                       | 49                 | 24.3          |
| T stage                   |                    |               |
| 1                         | 64                 | 31.7          |
| 2                         | 89                 | 44            |
| 3                         | 21                 | 10.4          |
| 4                         | 27                 | 13.4          |
| Unk                       | 1                  | 0.5           |
| N stage                   |                    |               |
| 0                         | 101                | 50            |
| 1                         | 82                 | 40.6          |
| 2                         | 10                 | 5             |
| 3                         | 6                  | 3             |
| Unk                       | 3                  | 1.4           |
| Tumor grade               |                    |               |
| G1                        | 5                  | 2.5           |
| G2                        | 100                | 49.5          |
| G3                        | 91                 | 45            |
| Unk                       | 6                  | 3             |
| Lymphovascular invasion   |                    |               |
| Yes                       | 41                 | 20.3          |
| No                        | 156                | 77.2          |
| Unk                       | 5                  | 2.5           |

| Number of patients | % of patients |
|-------------------|---------------|
| Neoadjuvant chemotherapy (NAC) |             |
| Yes               | 126           | 72.4          |
| No                | 76            | 37.6          |
| Type of NAC (N = 126) |             |
| EC → Taxane       | 94            | 74.6          |
| FEC → Taxane      | 21            | 16.7          |
| EC → CBDCA-Ptx    | 6             | 4.8           |
| Other             | 5             | 4             |
| Pathological complete response (N = 126) |             |
| Yes               | 43            | 34.1          |
| No                | 83            | 65.9          |
| Adjuvant chemotherapy (AC) |             |
| Yes               | 43            | 21.3          |
| No                | 159           | 78.7          |
| Type of AC (N = 43) |             |
| EC → Taxane       | 11            | 25.6          |
| FEC → Taxane      | 20            | 9.9           |
| Capecitabine      | 5             | 11.6          |
| Other             | 7             | 3.5           |
| Trastuzumab       | 53            | 26.2          |
| No                | 149           | 73.8          |
| Radiotherapy      | 174           | 86.1          |
| No                | 28            | 13.9          |
| Hormonotherapy    | 149           | 73.2          |
| No                | 54            | 26.8          |
| Type of hormonotherapy |             |
| SERM              | 56            | 37.6          |
| AI                | 79            | 53            |
| SERM + AI         | 14            | 9.4           |
| Relapse           | 28            | 13.9          |
| No                | 174           | 86.1          |

TNBC triple-negative breast cancer, Unk unknown, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy, EC epirubicin–cyclophosphamide, FEC 5-fluorouracil–epirubicin–cyclophosphamide, CBDCA carboplatin, Ptx paclitaxel, N number of patients, SERM selective estrogen receptor modulator, AI aromatase inhibitor
### Table 2  Kyn, Trp and Kyn/Trp ratio according to patient and tumor characteristics

| Comparison group          | Kyn (μM/L)          | Trp (μM/L)          | Kyn/Trp ratio |
|---------------------------|---------------------|---------------------|---------------|
|                           | Median ± SD         | P value             | Median ± SD   | P value         | Median ± SD   | P value         |
| Healthy vs. cancer        |                     |                     |               |                 |               |                 |
| Healthy                   | 1.951 ± 0.708       | < 0.0001***         | 48.80 ± 14.16 | 0.001**         | 0.042 ± 0.019 | 0.026*          |
| Cancer                    | 1.770 ± 0.537       |                     | 44.56 ± 10.83 |                 | 0.038 ± 0.013 |                 |
| Age (years)               |                     |                     |               |                 |               |                 |
| < 54.5                    | 1.738 ± 0.609       | < 0.0001***         | 45.68 ± 11.23 | 0.978           | 0.036 ± 0.015 | < 0.0001***     |
| ≥ 54.5                    | 1.980 ± 0.643       |                     | 46.63 ± 13.78 |                 | 0.043 ± 0.016 |                 |
| Histology                 |                     |                     |               |                 |               |                 |
| Ductal                    | 1.810 ± 0.550       | 0.077               | 44.51 ± 10.65 | 0.051           | 0.038 ± 0.014 | 0.005**         |
| Lobular                   | 1.550 ± 0.451       |                     | 48.60 ± 11.54 |                 | 0.033 ± 0.009 |                 |
| Other                     | 1.543 ± 0.289       |                     | 38.00 ± 10.92 |                 | 0.038 ± 0.008 |                 |
| Subtype                   |                     |                     |               |                 |               |                 |
| Luminal A                 | 1.770 ± 0.570       | 0.324               | 47.73 ± 12.48 | 0.213           | 0.038 ± 0.014 | 0.100           |
| Luminal B                 | 1.800 ± 0.458       |                     | 44.57 ± 10.27 |                 | 0.038 ± 0.011 |                 |
| HER2-enriched             | 1.853 ± 0.881       |                     | 40.42 ± 6.85  |                 | 0.047 ± 0.023 |                 |
| TNBC                      | 1.707 ± 0.442       |                     | 44.13 ± 9.90  |                 | 0.038 ± 0.012 |                 |
| Estrogen receptor expression |                 |                     |               |                 |               |                 |
| ER-positive               | 1.800 ± 0.510       | 0.897               | 45.47 ± 11.26 | 0.016*          | 0.0377 ± 0.012 | 0.040**         |
| ER-negative               | 1.757 ± 0.606       |                     | 42.00 ± 8.88  |                 | 0.042 ± 0.016 |                 |
| Progestosterone receptor expression |           |                     |               |                 |               |                 |
| PgR-positive              | 1.775 ± 0.480       | 0.890               | 44.93 ± 11.64 | 0.041*          | 0.038 ± 0.012 | 0.048*          |
| PgR-negative              | 1.760 ± 0.633       |                     | 43.73 ± 8.59  |                 | 0.041 ± 0.016 |                 |
| HER2 amplification        |                     |                     |               |                 |               |                 |
| HER2-positive             | 1.797 ± 0.643       | 0.364               | 43.66 ± 10.16 | 0.313           | 0.039 ± 0.017 | 0.100           |
| HER2-negative             | 1.766 ± 0.489       |                     | 44.93 ± 11.09 |                 | 0.038 ± 0.012 |                 |
| Ki67% expression          |                     |                     |               |                 |               |                 |
| Ki67 < 20%                | 1.757 ± 0.577       | 0.968               | 47.17 ± 1.02  | 0.240           | 0.038 ± 0.014 | 0.328           |
| Ki67 ≥ 20%                | 1.800 ± 0.518       |                     | 43.93 ± 10.06 |                 | 0.038 ± 0.013 |                 |
| TNM stage                 |                     |                     |               |                 |               |                 |
| Stage I                   | 1.652 ± 0.555       | 0.668               | 47.30 ± 12.75 | 0.035*          | 0.037 ± 0.011 | 0.143           |
| Stage II                  | 1.807 ± 0.489       |                     | 45.47 ± 10.18 |                 | 0.038 ± 0.014 |                 |
| Stage III                 | 1.697 ± 0.631       |                     | 40.60 ± 9.90  |                 | 0.042 ± 0.015 |                 |
| T stage                   |                     |                     |               |                 |               |                 |
| T1                        | 1.800 ± 0.538       | 0.935               | 48.58 ± 12.36 | 0.024*          | 0.037 ± 0.011 | 0.352           |
| T2                        | 1.757 ± 0.516       |                     | 44.47 ± 8.28  |                 | 0.038 ± 0.014 |                 |
| T3                        | 1.677 ± 0.642       |                     | 40.60 ± 12.31 |                 | 0.039 ± 0.016 |                 |
| T4                        | 1.807 ± 0.550       |                     | 41.23 ± 11.45 |                 | 0.043 ± 0.015 |                 |
| N stage                   |                     |                     |               |                 |               |                 |
| N0                        | 1.677 ± 0.515       | 0.736               | 44.67 ± 11.91 | 0.492           | 0.037 ± 0.013 | 0.538           |
| N1                        | 1.813 ± 0.503       |                     | 44.90 ± 9.95  |                 | 0.039 ± 0.013 |                 |
| N2                        | 1.705 ± 0.641       |                     | 44.20 ± 7.63  |                 | 0.044 ± 0.012 |                 |
| N3                        | 1.651 ± 1.106       |                     | 39.5 ± 8.60   |                 | 0.044 ± 0.022 |                 |
| Scarf–Bloom–Richardson grade |                 |                     |               |                 |               |                 |
| G1                        | 1.520 ± 0.522       | 0.143               | 40.60 ± 8.33  | 0.843           | 0.034 ± 0.005 | 0.026*          |
| G2                        | 1.670 ± 0.605       |                     | 44.40 ± 11.61 |                 | 0.036 ± 0.015 |                 |
| G3                        | 1.840 ± 0.450       |                     | 44.57 ± 10.20 |                 | 0.038 ± 0.011 |                 |
| Lymphovascular invasion   |                     |                     |               |                 |               |                 |
| Yes                       | 1.820 ± 0.657       | 0.286               | 45.47 ± 8.73  | 0.694           | 0.039 ± 0.014 | 0.272           |
| No                        | 1.728 ± 0.500       |                     | 44.35 ± 11.33 |                 | 0.038 ± 0.013 |                 |
In the cohort of cancerous patients, a statistically significant lower Trp level and higher Kyn/Trp ratio in plasma were observed for the ER− and PgR− patients compared to ER+ and PgR+ patients, respectively (Table 2). In particular, the values of circulating Trp were 42.00 ± 8.88 μM/L vs. 45.47 ± 11.26 μM/L (p 0.016) in ER− vs. ER+ and 42.00 ± 8.90 μM/L vs. 44.93 ± 11.64 μM/L (p 0.041) in PgR− and PgR+, respectively. The values of the plasmatic Kyn/Trp ratio were 0.042 ± 0.016 in ER− vs. 0.0377 ± 0.012 in ER+ patients (p 0.040) and 0.041 ± 0.016 in PgR− vs. 0.038 ± 0.012 in PgR+ patients (p 0.048). The correlation analysis showed a positive correlation between ER% and circulating Trp level and a negative correlation between PgR% and the Kyn/Trp ratio in plasma, as reported in Table 3 and in Additional file 1: Figure S3.

A lower plasmatic Kyn/Trp ratio for lobular carcinomas compared to the other histologies was also detected, particularly with a ratio of 0.033 ± 0.009 for lobular, 0.038 ± 0.014 for ductal and 0.038 ± 0.008 for other histologies (p 0.005). A comparison by pairs confirmed the difference between ductal and lobular carcinoma with a p value of 0.011 (Additional file 1: Table S1).

Moreover, the plasmatic Kyn/Trp ratio showed progressively higher values with increasing tumor grade, particularly 0.034 ± 0.005 for G1, 0.036 ± 0.015 for G2 and 0.038 ± 0.011 for G3 (p 0.026). The comparison by pairs did not confirm this difference (Additional file 1: Table S6), probably due to the low number of patients classified as G1.

We also observed a progressively lower circulating Trp level according to the increase of T (from 48.58 ± 12.36 μM/L in T1 to 41.23 ± 11.45 μM/L in T4, p 0.024) and TNM stage (from 47.30 ± 12.75 μM/L for Stage I to 40.60 ± 9.90 μM/L for Stage III, p 0.035). In particular, plasmatic Trp showed a significantly different distribution in the T1 tumor compared to T2-4 (p 0.003) and in Stage I compared to Stage II–III (p 0.014),
The Mann–Whitney U test. The comparison by pairs showed a statistically significant difference between T1 and T2 and between Stage I and Stage III (Additional file 1: Tables S3, S4). Likewise, a negative correlation between the plasmatic Trp level and tumor size expressed in mm was observed (Table 3 and Additional file 1: Figure S3).

Table 3  Correlation of Kyn, Trp and Kyn/Trp ratio with the continuous variables age, ER, PgR, Ki67 and size

| Variable (Unit) | Kyn | Trp | Kyn/Trp ratio |
|-----------------|-----|-----|--------------|
| Correlation coefficient | 95% CI | p value | Correlation coefficient | 95% CI | p value | Correlation coefficient | 95% CI | p value |
| Age (years)     | 0.295 | 0.196 to 0.389 | < 0.0001*** | 0.028 | −0.078 to 0.133 | 0.610 | 0.300 | 0.200 to 0.393 | < 0.0001*** |
| ER (%)          | 0.010 | −0.129 to 0.148 | 0.890 | 0.146 | 0.008 to 0.279 | 0.039* | −0.103 | −0.239 to 0.036 | 0.145 |
| PgR (%)         | −0.074 | −0.211 to 0.065 | 0.297 | 0.116 | −0.023 to 0.250 | 0.103 | −0.184 | −0.315 to −0.046 | 0.009** |
| Ki67 (%)        | −0.036 | −0.173 to 0.103 | 0.614 | −0.108 | −0.243 to 0.031 | 0.128 | 0.045 | 0.94 to 0.183 | 0.523 |
| Size (mm)       | 0.003 | −0.137 to 0.142 | 0.968 | −0.170 | −0.302 to −0.031 | 0.017* | 0.119 | −0.021 to 0.254 | 0.096 |

The correlation was calculated with the Spearman test. The correlation coefficient, 95% CI and p value are reported in the table. The significant correlations are reported in italics.

CI confidence interval, ER estrogen receptor, PgR progesterone receptor

Table 4  Kyn, Trp and Kyn/Trp ratio in breast cancer subtypes

| Group (N of pts) | Kyn | Trp | Kyn/Trp ratio |
|-----------------|-----|-----|--------------|
|                 | Median ± SD | p value | Median ± SD | p value | Median ± SD | p value |
| Luminal A (60 pts) | PCR (0) | NA | NA | NA | NA | NA |
|                 | No pCR (13) | 1.710 ± 0.684 | NA | 36.70 ± 8.26 | NA | 0.042 ± 0.019 | NA |
|                 | No relapse (53) | 1.775 ± 0.582 | 0.982 | 48.17 ± 13.02 | 0.442 | 0.038 ± 0.014 | 0.542 |
|                 | Relapse (7) | 1.717 ± 0.501 | 0.454 | 44.67 ± 5.88 | 0.043 ± 0.009 |
| Luminal B (89 pts) | PCR (23) | 1.887 ± 0.327 | 0.001** | 44.77 ± 14.17 | 0.455 | 0.045 ± 0.011 | 0.029* |
|                 | No pCR (42) | 1.580 ± 0.463 | 0.454 | 43.47 ± 8.51 | 0.036 ± 0.011 |
|                 | No relapse (79) | 1.807 ± 0.463 | 0.194 | 43.87 ± 10.53 | 0.447 | 0.038 ± 0.011 | 0.119 |
|                 | Relapse (10) | 1.653 ± 0.389 | 0.035 ± 0.006 |
| HER2-enriched (14 pts) | PCR (7) | 1.757 ± 0.790 | 0.234 | 39.73 ± 8.12 | 0.836 | 0.045 ± 0.018 | 0.295 |
|                 | No pCR (6) | 2.43 ± 0.956 | 0.454 | 42.42 ± 5.03 | 0.063 ± 0.028 |
|                 | No relapse (10) | 1.828 ± 0.786 | 0.454 | 37.80 ± 6.67 | 0.076 | 0.047 ± 0.023 | 1 |
|                 | Relapse (4) | 2.398 ± 1.135 | 0.454 | 46.13 ± 2.94 | 0.049 ± 0.026 |
| TNBC (39 pts) | PCR (13) | 1.707 ± 0.476 | 0.853 | 44.43 ± 7.98 | 0.511 | 0.037 ± 0.008 | 0.353 |
|                 | No pCR (22) | 1.777 ± 0.449 | 0.454 | 41.97 ± 10.87 | 0.042 ± 0.013 |
|                 | No relapse (39) | 1.648 ± 0.450 | 0.707 | 44.78 ± 10.73 | 0.440 | 0.037 ± 0.012 | 0.761 |
|                 | Relapse (7) | 1.813 ± 0.437 | 0.454 | 42.00 ± 4.65 | 0.042 ± 0.011 |

The corresponding p values for patients showing or not a pCR and for patients with or without relapse are reported in the table. A significance level of 0.05 is accepted (in italics).

Median value of Kyn, Trp and Kyn/Trp ratio in the different breast cancer subtypes according to the response to chemotherapy and relapse tested by the mean of the Mann–Whitney U test.

Kyn kynurenine, Trp tryptophan, SD standard deviation, PCR pathological complete response, TNBC triple-negative breast cancer.

For all the other variables (BC subtype, HER2 expression, Ki67 expression, N stage and lympho-vascular invasion), we did not observe any differences in circulating Kyn, Trp and the Kyn/Trp ratio distribution, as shown in Table 2 and in Additional file 1: Tables S1–S6.

In addition to the association of plasmatic Kyn, Trp and the Kyn/Trp ratio with cancer characteristics, we also analyzed their predictive roles in the response.
to chemotherapy and cancer relapse (Table 2). We observed a statistically significant higher circulating Kyn level for patients experiencing a pathological complete response (pCR) after NAC in 126 patients, with a value of 1.813±0.470 μM/L vs. 1.650±0.589 μM/L (p = 0.039), but no differences in plasmatic Trp or the Kyn/Trp ratio were detected. Considering the different breast cancer subtypes, we detected a higher plasmatic Kyn (1.887±0.327 μM/L vs. 1.580±0.463 μM/L, p = 0.001) and Kyn/Trp ratio (0.045±0.011 vs. 0.036±0.011, p = 0.029) for Luminal B patients who reached a pCR compared with patients with residual disease, but not significant association for the other subtypes (Table 4). No significant difference was detected in the four subtypes between patients experiencing a relapse and those not (Table 4). Interestingly, we observed a higher Kyn median value, a lower Trp and a higher Kyn/Trp ratio in plasma in TNBC with residual disease and in patients who relapsed, even if the significance level was not reached.

We classified BC patients into different groups according to circulating Kyn, Trp and the Kyn/Trp levels using the median value in the cancerous patients as the threshold: 1.77 μM/L for Kyn, 44.56 μM/L for Trp and 0.038 for the Kyn/Trp ratio. We analyzed DFS and BCSS in these groups. Six patients of 202 of the BC cohort were not evaluable for survival due to deaths from other causes or loss during follow-up. Among the 196 patients included in the analysis for survival, we detected 28 progressions and 8 deaths. We detected a non statistically significant difference in DFS in the groups with low and high plasmatic Kyn/Trp ratio (Fig. 2c), with a 5-year DFS of 85% vs. 73% (p = 0.523), respectively. For all the other variables (low and high circulating kyn and Trp), we did not observe any difference in the groups analyzed (Fig. 2 and Table 5).

The analysis of DFS and BCSS in the different BC subtypes according to circulating Kyn, Trp and the Kyn/Trp ratio did not show significant results (Additional file 1: Figures S1, S2).
Discussion

In this study, we analyzed Kyn and Trp levels and their ratios in the plasma of early BC patients and healthy CTRLs. To our knowledge, this is the largest study evaluating the plasmatic level of Trp and its metabolite Kyn in this setting of patients. The aim of our study was to identify a difference in circulating Kyn, Trp and the Kyn/Trp level in the presence of a BC, according to BC characteristics and their predictive role on survival, as observed in other malignancies.

We met our primary objective to demonstrate the difference in plasmatic Kyn, Trp and the Kyn/Trp ratio between BC patients and healthy CTRLs. Overall, we observed lower Kyn and Trp levels in plasma of cancerous patients, suggesting rapid Trp catabolism, with a possible accumulation of downstream metabolites, such as quinolinic and kynurenic acid. The same results were shown by Greene and colleagues in a cohort of 77 BC patients compared to 40 healthy CTRLs [24]. These authors also analyzed the plasma level of nicotinamide, the final metabolite of Trp catabolism. They observed an accumulation of nicotinamide relative to the Trp level in plasma of BC patients, which suggests hyperactivation of the catabolic pathway [24]. In our study, we also found a higher plasmatic Kyn/Trp ratio in healthy CTRLs than in BC patients. These results are not consistent with those shown in a previously published study by Lyon and colleagues, but we note that the sample in this paper comprised only 57 subjects vs. 348 in our study [23]. Our finding of a lower circulating Trp level concomitant with a higher Kyn/Trp ratio in HR− tumors. Considering the known immunosuppressive role of Kyn and the fact that HR− BCs are associated with a higher immune infiltration, we could not associate the difference in immune system activation throughout breast cancer subtypes with the plasmatic Kyn/Trp ratio. In fact, plasmatic Kyn and Trp levels reflect the systemic Trp catabolism and could not be considered a reflection of tumor microenvironment, in which the local enzymatic activity determines the level of metabolites at tumor site.

In stage I tumors compared to Stage II and III tumors and in T1 tumors compared to T2-4 tumors, we observed a higher plasmatic Trp level, suggesting faster Trp degradation in larger tumors.

In the whole cohort of patients receiving NAC, we observed a higher level of circulating Kyn in patients experiencing a pCR without any statistically significant difference in Trp level or in the Kyn/Trp ratio in plasma, while in the Luminal B subtype only, the high Kyn level for patients with pCR was concomitant with a significant increase in the Kyn/Trp ratio in plasma samples. This is in contrast with what was expected, considering the immunosuppressive role of Kyn and the known

Table 5 DFS and BCSS according to Kyn, Trp and the Kyn/Trp ratio

| Outcome Parameter | Kyn     | Trp     | Kyn/Trp ratio |
|-------------------|---------|---------|--------------|
|                   | Low     | High    | p value | Low     | High    | p value | Low     | High    | p value |
| DFS               |         |         |         |         |         |         |         |         |         |
| N patients        | 100     | 96      | NA      | 95      | 101     | NA      | 98      | 98      | NA      |
| N events          | 14      | 14      | NA      | 11      | 17      | NA      | 13      | 15      | NA      |
| 5-year-DFS        | 80%     | 79%     | 0.994   | 81%     | 78%     | 0.602   | 85%     | 73%     | 0.523   |
| HR (95% CI)       | 1.003 (0.477–2.106) | 1.224 (0.572–2.616) | 1.273 (0.605–2.679) |
| BCSS              |         |         |         |         |         |         |         |         |
| N patients        | 94      | 94      | NA      | 90      | 98      | NA      | 93      | 95      | NA      |
| N events          | 6       | 2       | NA      | 5       | 3       | NA      | 5       | 3       | NA      |
| 5-year-BCSS       | 92%     | 98%     | 0.167   | 94%     | 96%     | 0.288   | 94%     | 97%     | 0.586   |
| HR (95% CI)       | 0.341 (0.069–1.691) | 0.469 (0.112–1.964) | 0.673 (0.161–2.822) |

Kyn kynurenine, Trp tryptophan, DFS disease-free survival, N number, HR hazard ratio, BCSS breast cancer-specific survival

not only of TDO but also of KNYNU in TNBC cell lines [26].
association of pCR with TIL infiltration [29, 30]. In addition, in TNBC with residual disease and with relapse, it is interesting to observe a higher Kyn median value, a lower Trp and a higher Kyn/Trp ratio. However, the TNBC subgroup of our cohort comprised only 39 patients, and these results did not reach significance. Nevertheless, this study analyzes only Trp and its metabolites in plasma, and we cannot exclude a role for Trp catabolism in the tumor microenvironment.

Finally, we did not observe any association between plasmatic Kyn, Trp or their ratio with survival, in contrast to what was observed for other cancer types. In fact, previously published studies showed a significant association between a low Kyn/Trp ratio in plasma and longer survival in non-small cell lung cancer (NSCLC) treated with chemoradiation [14, 15] or immunotherapy [16].

The present study is the largest analyzing plasmatic Kyn and Trp levels in BC and in healthy CTRLs. This high number of patients allows us to compare the plasmatic concentrations of these metabolites between breast cancer subtypes, disease stage, proliferation marker expression, tumor grade, clinical outcome and response to chemotherapy. In no other previous studies the Trp and Kyn levels were so well described according to tumor characteristics, probably due to the smallest sample size. The plasmatic Trp level could be related to fasting, that is a missing information in our cohort. In the second instance, we did not measure the circulating downstream metabolites after Kyn, which could be useful for better understanding the variations in Trp catabolism at any level of the pathway. Moreover, we have to take into account that other enzymes are involved in Trp catabolism, as well the metabolic pathway at the tumor level could be different from systemic catabolism and not necessarily reflected in circulating metabolite-level modification. Consequently, we cannot consider plasmatic Kyn and Trp levels as a direct reflection of IDO activity in tumor tissue. An analysis of the tumor site in addition to the plasmatic measurement of Trp and its metabolites could be useful to clarify the correspondence between the circulating and tumor compartments. Finally, a longer follow-up could be useful for the survival analysis. In our cohort, we observed only 28 events of progression and 8 of death out of 196 patients evaluated for outcome, which did not allow us to obtain conclusive results regarding survival.

Conclusions
In our study, we showed that plasmatic levels of Kyn, Trp and the Kyn/Trp ratio could differentiate BC patients from healthy CTRLs, but they were not useful for predicting the outcome or sensitivity to chemotherapy. According to the above observations, breast cancer is associated with rapid metabolism that could be systemic or local.

Additional file

| Abbreviations |
|----------------|
| ARH: aryl hydrocarbon receptor; BCSS: breast cancer specific survival; CTRL: control; DC: dendritic cell; DFS: disease free survival; ER: estrogen receptor; HR: hormone receptor; IDO: indoleamine 2,3-dioxygenase; ILT3: immunoglobulin-like transcript 3; ILT4: immunoglobulin-like transcript 4; Kyn: kynurenine; KYNU: kynureninase; NAC: neoadjuvant chemotherapy; PC (or pCR): pathological complete response; PgR: progesterone receptor; TDO: tryptophan 2,3-dioxygenase; TNBC: triple negative breast cancer; Treg: T regulatory; Trp: tryptophan. |

Acknowledgements
We acknowledge the Institutional Biobank (BHUL–Université de Liège–CHU de Liège, Belgium).

Authors’ contributions
CEO: study design, sample analysis, data collection, statistical analysis, manuscript writing. FB: study design, sample analysis, manuscript revision. CJ: study design, statistical analysis, manuscript revision. SL: sample analysis. VB: study design, manuscript revision. GF: study design, manuscript revision. All authors read and approved the final manuscript.

Funding
This work was supported by the Belgian Fund for Scientific Research (F.R.S.-FNRS), Fondation contre le cancer, FIRS CHU Liège and Fondation Léon Fredericq.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki. The institutional ethics committee of the University Hospital of Liège (Belgium) approved the protocols under the following committee’s reference numbers: 2010/252; 2013/214 and 2013/215.

Consent for publication
Each patient or healthy control signed informed consent before inclusion in the trial, including acceptance for data publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Medical Oncology Department, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium. 2 Laboratory of Human Genetics, GIGA Research Institute, Liège, Belgium. 3 Department of Human Genetics, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium. 4 Liège University, Liège, Belgium. 5 Liège University, Liège, Belgium.
References

1. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21):5435–40.

2. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Pendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound 1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7.

3. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain. 2009;2:8.

4. Chang MY, Smith C, Duhadaway JB, Pyle JR, Boulden J, Soler AP, et al. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther. 2011;12(12):1050–8.

5. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, 3rd, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3-dioxygenase. Proc Natl Acad Sci USA. 2008;105(44):17073–8.

6. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006;12(4):1144–51.

7. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Funakoshi H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006;95(11):1553–61.

8. Okamoto A, Nikaiko T, Ochii K, Takakura S, Mio K, Aoki Y, et al. Indoleamine 2,3-dioxygenase expression as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005;11(16):6030–9.

9. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takakawa O, et al. Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007;98(6):874–81.

10. Witkiewicz A, Williams TK, Czeczotto J, Durban K, Showalter SL, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008;206(5):849–56.

11. Brody JR, Costantino CL, Berger AC, Tao T, Lisanti MP, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle. 2009;8(12):1930–4.

12. Seeber A, Klinglmair G, Fritz J, Steinkohl F, Zimmer KC, Aigner F, et al. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Sci. 2018;109(5):583–91.

13. Cerejido BC, Antonia S, Bepler G, Garrett JJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013;2(3):e23428.

14. Wang W, Huang L, Lin JY, Jolly S, Zang Y, Wu H, et al. IDO immune status after chemoradiation may predict survival in lung cancer patients. Cancer Res. 2018;78(3):800–16.

15. Botticelli A, Cariembelli B, Lionetto L, Zizzari L, Salati M, Pisano A, et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018;16(1):219.

16. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22(5):633–42.

17. Brenk M, Scheler M, Koch S, Neumann J, Takakawa O, Hacker G, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+Foxp3+ T regulatory cells. J Immunol. 2009;183(1):145–54.

18. Kemmer P, Bauer TM, Röse L, Dufert C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196(4):447–57.

19. Frumento G, Rotondo R, Tonetti M, Damante G, Benatti U, Ferrara GB. Tryptophan-derived carboxylates are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196(4):459–68.

20. Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, et al. Analysis of indoleamine 2-3-dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother. 2013;62(5):829–37.

21. Chen JY, Li CT, Kuo CC, Tsai KK, Hou MF, Hung WC. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res. 2014;16(4):410.

22. Lyon DE, Walter JM, Starkweather AR, Schubert CM, McCain NL. Tryptophan degradation in women with breast cancer: a pilot study. BMC Res Notes. 2011;4:156.

23. Greene Li, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, et al. A role for tryptophane-2,3-dioxygenase in CD8 T cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma. Mol Cancer Res. 2019;17(1):131–9.

24. Tsy C, Lin CC, Spasojevic I, Iversen ES, Chi JT, Marks JR, et al. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res. 2014;16(4):413.

25. D'Amato NC, Rogers TJ, Gordon MA, Greene Li, Cochrane DR, Spoelstra NS, et al. A TDO2-AHR signaling axis facilitates anokis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2013;75(21):4651–64.

26. De Bie J, Guest J, Guillemin GJ, Grant R. Central kynurenine pathway shift with age in women. J Neurochem. 2016;136(5):995–1003.

27. Refaey ME, McGee-Lawrence ME, Fulzele S, Kennedy EJ, Bollag WB, Elsanty M, et al. Kynurenine, a tryptophan metabolite that accumulates with age, induces bone loss. J Bone Miner Res. 2017;32(1):2182–93.

28. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.

29. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Indolyl-3-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7.

30. Onesti et al. J Transl Med          (2019) 17:239